Marshall Wace LLP Takes Position in COMPASS Pathways plc (NASDAQ:CMPS)

Marshall Wace LLP bought a new stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 369,070 shares of the company's stock, valued at approximately $1,395,000. Marshall Wace LLP owned 0.54% of COMPASS Pathways as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock worth $266,000 after acquiring an additional 25,970 shares in the last quarter. Franklin Resources Inc. grew its stake in COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company's stock worth $1,810,000 after purchasing an additional 12,599 shares during the period. Green Alpha Advisors LLC increased its holdings in COMPASS Pathways by 138.3% in the fourth quarter. Green Alpha Advisors LLC now owns 37,614 shares of the company's stock worth $142,000 after purchasing an additional 21,833 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in COMPASS Pathways by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company's stock valued at $661,000 after buying an additional 26,787 shares during the period. Finally, Flagship Harbor Advisors LLC bought a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $43,000. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Stock Up 2.2 %

NASDAQ CMPS traded up $0.09 during trading hours on Friday, hitting $4.19. The company's stock had a trading volume of 630,372 shares, compared to its average volume of 798,868. The company has a market capitalization of $388.30 million, a PE ratio of -1.90 and a beta of 2.34. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 52 week low of $2.49 and a 52 week high of $9.63. The company's 50-day simple moving average is $3.34 and its two-hundred day simple moving average is $4.10.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). Research analysts anticipate that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CMPS. Royal Bank of Canada reiterated an "outperform" rating and set a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Canaccord Genuity Group cut their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways presently has a consensus rating of "Buy" and an average price target of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.